However, the decreased infectious virus production observed with JR-AB2-011 treatment is interesting considering previously published work that observed that the inhibition of the downstream Akt pathway increased the effects of rapamycin in treating EBV+ B-cell lymphomas [50]. The gene discussed is AKT1; the disease is B-cell non-Hodgkin lymphoma.